Alto Neuroscience

colorful brain art model
Biotech

Alto halts work on PDE4 inhibitor after ph. 2 schizophrenia fail

Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study.
James Waldron Apr 2, 2026 7:17am
success failure signposts

Alto's phase 2 depression trial misses primary efficacy endpoint

Jun 26, 2025 9:28am
balloon missed target pop arrows miss failure

Boehringer's schizophrenia drug fails trio of phase 3 trials

Jan 16, 2025 11:58am
failure crash no fail rocket cancelled end

Alto's midphase depression trial falls flat

Oct 23, 2024 4:47am
parasail Blue Lagoon parachute

CRISPR Tx, Novartis, Cour & more—Chutes & Ladders

May 24, 2024 8:30am
Graphic of an open door with the words exit above it

Biogen CMO heads for the exits

Mar 15, 2024 10:51am